Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: An actigraphic study

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: poor sleep is common in MS and it contributes to fatigue. The β interferons produce systemic effects which may not adapt and may induce fatigue. Objective: to verify whether subjective poor sleep and fatigue during chronic therapy correspond to reduced sleep efficiency obtained by actigraphy at home. Methods: 42 ambulatory relapsing remitting MS patients with mild disability were monitored for at least 7 nights. Habitual sleep quality and fatigue were assessed with the MOS sleep measure and the Fatigue Severity Scale. Sleep logs provided daily sleep quality assessments during actigraphy at home. Patients were grouped according to their current treatment: no therapy, glatiramer acetate, IFNβ 3 times a week, and IFNβ once a week. Results and Conclusion: sleep efficiency was reduced by an average of 5% in 2/3 of the nights following IFNβ injections compared to the other nights, and daily sleep ratings correlated with actigraphy. Patients on glatiramer acetate also showed a lower sleep efficiency than patients without therapy. Actigraphy data were only modestly correlated with MOSsm scores, not with fatigue. Long term adaptation of sleep effects of immunomodulant agents is incomplete and needs to be considered in treatment planning and assessment of sleep in MS.

Original languageEnglish
Pages (from-to)238-247
Number of pages10
JournalMultiple Sclerosis Journal
Volume16
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Fatigue
Sleep
Actigraphy
Therapeutics
Interferons

Keywords

  • Actigraphy
  • Chronic therapy
  • Fatigue
  • Glatiramer acetate
  • Interferon β
  • Multiple sclerosis
  • Side effects
  • Sleep

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{239b937d39ed44159a34cae7ad26d6aa,
title = "Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: An actigraphic study",
abstract = "Background: poor sleep is common in MS and it contributes to fatigue. The β interferons produce systemic effects which may not adapt and may induce fatigue. Objective: to verify whether subjective poor sleep and fatigue during chronic therapy correspond to reduced sleep efficiency obtained by actigraphy at home. Methods: 42 ambulatory relapsing remitting MS patients with mild disability were monitored for at least 7 nights. Habitual sleep quality and fatigue were assessed with the MOS sleep measure and the Fatigue Severity Scale. Sleep logs provided daily sleep quality assessments during actigraphy at home. Patients were grouped according to their current treatment: no therapy, glatiramer acetate, IFNβ 3 times a week, and IFNβ once a week. Results and Conclusion: sleep efficiency was reduced by an average of 5{\%} in 2/3 of the nights following IFNβ injections compared to the other nights, and daily sleep ratings correlated with actigraphy. Patients on glatiramer acetate also showed a lower sleep efficiency than patients without therapy. Actigraphy data were only modestly correlated with MOSsm scores, not with fatigue. Long term adaptation of sleep effects of immunomodulant agents is incomplete and needs to be considered in treatment planning and assessment of sleep in MS.",
keywords = "Actigraphy, Chronic therapy, Fatigue, Glatiramer acetate, Interferon β, Multiple sclerosis, Side effects, Sleep",
author = "Laura Mendozzi and Federica Tronci and Massimo Garegnani and Luigi Pugnetti",
year = "2010",
month = "2",
doi = "10.1177/1352458509354551",
language = "English",
volume = "16",
pages = "238--247",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy

T2 - An actigraphic study

AU - Mendozzi, Laura

AU - Tronci, Federica

AU - Garegnani, Massimo

AU - Pugnetti, Luigi

PY - 2010/2

Y1 - 2010/2

N2 - Background: poor sleep is common in MS and it contributes to fatigue. The β interferons produce systemic effects which may not adapt and may induce fatigue. Objective: to verify whether subjective poor sleep and fatigue during chronic therapy correspond to reduced sleep efficiency obtained by actigraphy at home. Methods: 42 ambulatory relapsing remitting MS patients with mild disability were monitored for at least 7 nights. Habitual sleep quality and fatigue were assessed with the MOS sleep measure and the Fatigue Severity Scale. Sleep logs provided daily sleep quality assessments during actigraphy at home. Patients were grouped according to their current treatment: no therapy, glatiramer acetate, IFNβ 3 times a week, and IFNβ once a week. Results and Conclusion: sleep efficiency was reduced by an average of 5% in 2/3 of the nights following IFNβ injections compared to the other nights, and daily sleep ratings correlated with actigraphy. Patients on glatiramer acetate also showed a lower sleep efficiency than patients without therapy. Actigraphy data were only modestly correlated with MOSsm scores, not with fatigue. Long term adaptation of sleep effects of immunomodulant agents is incomplete and needs to be considered in treatment planning and assessment of sleep in MS.

AB - Background: poor sleep is common in MS and it contributes to fatigue. The β interferons produce systemic effects which may not adapt and may induce fatigue. Objective: to verify whether subjective poor sleep and fatigue during chronic therapy correspond to reduced sleep efficiency obtained by actigraphy at home. Methods: 42 ambulatory relapsing remitting MS patients with mild disability were monitored for at least 7 nights. Habitual sleep quality and fatigue were assessed with the MOS sleep measure and the Fatigue Severity Scale. Sleep logs provided daily sleep quality assessments during actigraphy at home. Patients were grouped according to their current treatment: no therapy, glatiramer acetate, IFNβ 3 times a week, and IFNβ once a week. Results and Conclusion: sleep efficiency was reduced by an average of 5% in 2/3 of the nights following IFNβ injections compared to the other nights, and daily sleep ratings correlated with actigraphy. Patients on glatiramer acetate also showed a lower sleep efficiency than patients without therapy. Actigraphy data were only modestly correlated with MOSsm scores, not with fatigue. Long term adaptation of sleep effects of immunomodulant agents is incomplete and needs to be considered in treatment planning and assessment of sleep in MS.

KW - Actigraphy

KW - Chronic therapy

KW - Fatigue

KW - Glatiramer acetate

KW - Interferon β

KW - Multiple sclerosis

KW - Side effects

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=76449087607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76449087607&partnerID=8YFLogxK

U2 - 10.1177/1352458509354551

DO - 10.1177/1352458509354551

M3 - Article

C2 - 20028705

AN - SCOPUS:76449087607

VL - 16

SP - 238

EP - 247

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 2

ER -